Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
Senti Biosciences Dividend Announcement
• Senti Biosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Senti Biosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.
Senti Biosciences Dividend History
Senti Biosciences Dividend Yield
Senti Biosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Senti Biosciences stock? Use our calculator to estimate your expected dividend yield:
Senti Biosciences Financial Ratios
Senti Biosciences Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Senti Biosciences stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.